Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

NCT04010968 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Intermediate Risk Chronic Lymphocytic Leukemia
Fit Patients
Risk-Adapted and MRD-Driven Strategy

Interventions

DRUG: venetoclax and ibrutinib (I+VEN)
DRUG: FCR

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]
[object Object]